On November 5, 2021, Beijing Airdoc Technology Development Co., Ltd. (HKEX: 2251) (“Airdoc”) was officially listed on Hong Kong Exchanges and Clearing Limited.  UBS Securities Hong Kong Limited and CLSA Capital Markets Limited acted as co-sponsors for this issuance.

The Airdoc is one of the first companies in China that provides noninvasive, quick, effective, and expandable early detection, diagnosis, and health risk evaluating solution of AI-based retinal image identification.  The independently developed core product Airdoc-AIFUNDUS (1.0) among its product portfolio is an AI-based medical device software, which is approved to provide aided diagnosis of diabetic retinopathy and assists the doctors in the medical diagnosis.  It is the first medical device of its kind to be granted the third-class medical device certificate by the National Medical Products Administration.

As the intellectual property legal consultant for this listing of Airdoc, Liu Shen provided a full range of intellectual property legal services for this project, with the attorney team including Dr. Stephen Zou as the signing attorneys, and Mr. Zhang Guidong, Mr. Liu Guojun and etc. as project participants.